Fig. 6.

Combination of CQ and taselisib potentiates paclitaxel antitumor effect in vivo TNBC xenograft models. a MDAMB231 cells (7 × 10⁶) were s.c. injiected in NOD/SCID mice as described in Methods section. When established tumors were palpable, mice were treated with 1) vehicles (CTL group) 2)taselisib (5 mg/kg/os) daily 3)CQ (30 mg/kg/os) daily 4)paclitaxel (10 mg/Kg/IP) weekly 5)taselisib + CQ daily and 6)taselisib + paclitaxel 7)paclitaxel + CQ 8)triple combination. Treatment lasted 2 weeks followed by 1 week of follow-up. Relative tumor volume curves are represented as means ± SE measured at pre-specified time points. Inset, body weight have been measured two times/week. Statistically significant results are reported (*** indicates P < 0.0005, ** indicates P < 0.005 and * indicates P < 0.05). b Tumour volume averages from each group at day 0 and day 22 were compared and presented as percentages of vehicle. c Tumor growth delay (TGD) determined as %TGD = [(T − C) /C] × 100, where T and C are the mean times expressed in days for the treated or control groups, respectively, to reach a defined tumor volume (see Materials and Methods). d Representative images of tumors collected ex vivo on day 28 e Tumor volume ex vivo on day 28 represented as means ± SE (f) Tumor weight ex vivo on day 28 represented as means ± SE